

**INFORMATION DISCLOSURE STATEMENT**

Applicant	:	Weiner et al.
App. No	:	10/761,787
Filed	:	January 21, 2004
For	:	USE OF N-DESMETHYLCLOZAPINE TO TREAT HUMAN NEUROPSYCHIATRIC DISEASE
Examiner	:	Jennifer M. KIM
Art Unit	:	1617
Confirm. No	:	3544

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 52 references to be considered by the Examiner. Also enclosed are 38 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

An English translation of References 16, 35, and 36 was not available. The relevance of these references is believed to be the chemical structure depicted therein.

An English translation of References 27, 30, and 34 was not available. Their relevance was noted in the Russian Examination Report dated October 18, 2007 (Reference 52) an English language translation thereof is provided.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the

**Appl. No.** : 10/761,787  
**Filed** : January 21, 2004

**Docket No.** ACADIA.031A  
**Customer No.** 20,995

fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 3-3-08

By: Ryan E. Melnick

Ryan E. Melnick  
Registration No. 58,621  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

4954159:abt  
022908